Condition: Type 1 Diabetes · New Onset · Sponsor: City of Hope Medical Center
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
This description comes directly from the study's public registry record.
Robert Henderson, MS · 813-975-8690 · rhenderson@jaeb.org
Always discuss trial participation with your own doctor first.
| UCSF | San Francisco, California, United States | Recruiting |
| Barbara Davis Center for Diabetes University of Colorado Anschutz | Aurora, Colorado, United States | Not Yet Recruiting |
| Yale University | New Haven, Connecticut, United States | Not Yet Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| University of Buffalo | Buffalo, New York, United States | Recruiting |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07061574